Quality of life in alopecia areata: a study of 60 cases

M Dubois et al.
Quality of Life in Alopecia Areata Hegemann L, Forstinger C, Partsch B et al. (1995) Nowak A, Klimowicz A (1990) 2-Stage penetra- Roos K, Brorson JE (1990) oncentration of Microdialysis in cutaneous pharmacology— tion of a single oral dose of sulfadimethoxine phenoxymethylpenicillin in tonsillar tissue.
kinetic-analysis of transdermally delivered into skin blister fluid. Eur J Clin Pharmacol nicotine. J Investig Dermatol 104:839–43 Jynge P, Skjetne T, Gribbestad I et al. (1990) Pershing LK, Nelson JL, Corlett JL et al.
et al. (1999) Bioavailability of clobetasol propionate—quantification of drug concen- fluorine magnetic-resonance spectroscopy— trations in the stratum corneum by dermato- a study of liver and muscle disposition of fleroxacin in humans. Clin Pharmacol Ther Quality of Life in Alopecia Areata: A Study of 60 Cases Journal of Investigative Dermatology (2010) 130, 2830–2833; published online 19 August 2010 skin disorders’’-specific Qol instru- affected and symptoms the least one.
Qol for almost all the SF36 dimensions.
leisure activity, daily life, and physical adherence to the Helsinki guidelines.
pathic urticaria, and atopic dermatitispatients; (ii) being less bothered totreatment-induced Abbreviations: AA, alopecia areata; Qol, quality of life; SF36, short form 36 2830 Journal of Investigative Dermatology (2010), Volume 130 Table 1. Quality-of-life indicative comparisons between AA patients and other dermatological conditions, andFrench age- and sex-matched controls1 37.4±24.7 o0.001 23.8±21.8 o0.001 34.2±24.6 o0.001 0.145 36.2±20.4 o0.001 35.5±21.3 o0.001 49.3±25.2 o0.001 50.3±25.5 o0.001 50.1±25.5 o0.001 47.2±29.3 o0.001 36.7±28.1 o0.001 46.7±27.9 o0.001 Treatment restrictions 30.3±30.2 35.8±34.0 44.4±28.2 o0.001 61.4±23.7 o0.001 69.8±21.3 o0.001 Abbreviations: AA, alopecia areata; AD, atopic dermatitis; CU, chronic urticaria; HS, hidradenitis suppurativa; NF1, neurofibromatosis type 1; PSO,psoriasis; SF36, short form 36.
2SF36, 36 items, eight dimensions (range (0–100), 0 lowest and 100 highest level of Qol; 3VQ-Dermato, 28 items, seven domains and one overall score (range (0–100), 0 highest and 100 lowest level of Qol; 4Skindex, 29 items, three domains (range (0–100), 0 highest and 100 lowest level of Qol; Bold values Po0.05.
Table 2. Associations between VQ-Dermato dimension scores and global score, and sociodemographic/clinicalcharacteristics in 60 alopecia areata (AA) patients M Dubois et al.
Quality of Life in Alopecia Areata 1Mean ± SD, P: P-value Mann–Whitney test.
2Spearman’s correlation coefficient, P: P-value Spearman’s test.
3Course of the disease was defined as ‘‘unstable’’ if there was alternation of worsening and improvement phases in the last 2 years, and ‘‘stable’’ otherwise.
4Severity 1: visual analog scale by reference to the cases of AA seen in daily practice; 0 ‘‘patient among the least affected’’ and 100 ‘‘patient among the mostaffected’’.
5Severity 2: visual analog scale by reference to the cases of all skin disorders seen in daily practice; 0 ‘‘patient among the least affected’’ and 100 ‘‘patientamong the most affected’’.
Bold values: Po0.05.
2832 Journal of Investigative Dermatology (2010), Volume 130 Cash TF (1999) The psychosocial consequences of androgenetic alopecia: a review of the research Chren MM, Lasek RJ, Flocke SA et al. (1997) Improved discriminative and evaluative cap-ability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 133:1433–40 Chren MM, Lasek RJ, Quinn LM et al. (1996) clinical parameters (data not shown).
patients with skin disease: reliability, validity,and responsiveness. J Invest Dermatol 107: atically search for other health disorders Coste J (2001) Medical Outcome Study Short Form Firooz A, Firoozabadi MR, Ghazisaidi B et al.
(2005) Concepts of patients with alopecia areata about their disease. BMC Dermatol5:1 Grob JJ, Auquier P, Dreyfus I et al. (2009) How to prescribe antihistamines for chronic idio- pathic urticaria: desloratadine daily versus PRN and quality of life. Allergy 64:605–12 and also mental health and social life. It Grob JJ, Auquier P, Martin S et al. (1999) Development and validation of a quality oflife measurement for chronic skin disorders in french: VQ-Dermato.The Reseau d’ Epi- Grob JJ, Revuz J, Ortonne JP et al. (2005) Comparative study of the impact of chronicurticaria, psoriasis and atopic dermatitis on Gulec AT, Tanriverdi N, Duru C et al. (2004) The role of psychological factors in alopecia The authors state no conflict of interest.
areata and the impact of the disease on thequality of life. Int J Dermatol 43:352–6 Leplege A, Ecosse E, Pouchot J et al. (2001) MOS ACKNOWLEDGMENTSThis work was supported by institutional grants SF36 Questionnaire. Manual and Guidelines from the PHRC 2005 (Program Hospitalier Recherche for Scores’ Interpretation. Vernouillet: Estem, Leplege A, Ecosse E, Verdier A et al. (1998) tion, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol Leplege A, Ecosse E, Zeller J et al. (2003) France). Adaptation and assessment of psycho- 1Department of Dermatology, Sainte-Marguerite Hospital, Marseille, France; 2Department of Wolkenstein P, Loundou A, Barrau K et al. (2007) Clinical Research, Assistance Publique des Quality of life impairment in hidradenitis Hoˆpitaux de Marseille, Marseille, France; suppurativa: a study of 61 cases. J Am Acad EA3279 ‘‘Self-Perceived Health Assessment’’ Research Unit and Department of Public Health, Wolkenstein P, Zeller J, Revuz J et al. (2001) Nord Hospital, Universite´ de la Me´diterrane´e, Quality-of-life impairment in neurofibroma- tosis type 1: a cross-sectional study of 128

Source: http://www.iresp.net/files/2013/04/48-Dubois-et-al-2010.pdf